SSB and Lonza modify relationship for supply of cell culture media

18 Nov 2018

Sartorius Stedim Biotech will continue to offer Lonza media and buffer products but under a non-exclusive agreement.

Sartorius Stedim Biotech (SSB) and Lonza have modified their current agreement for supply of cell culture media by mutual accord. The agreement, signed in 2012, gave SSB exclusive sales and marketing rights for certain cell culture media and buffers developed and manufactured by Lonza for use in biopharmaceutical manufacturing processes. Lonza retained sales for research-based products, among others.

SSB and Lonza modify relationship for supply of cell culture media

Under new agreements, SSB will continue to offer current and future Lonza media and buffers on a non-exclusive basis as part of its extensive portfolio of products for cell-based development and manufacturing. Lonza Pharma & Biotech resumes sales and marketing of all its media products for both manufacturing and research. Customers of both companies will continue to be able to source media products for their specific needs.

“We have a long-standing and productive partnership with SSB and we will continue to work together to provide solutions for customers as they bring medicines to patients,” said Marc Funk, COO Lonza Pharma & Biotech. “As new generations of complex biologics move towards commercial production, media is no longer viewed a consumable but a critical part of the package we offer customers developing next-generation therapies, and we are investing accordingly in this area.”

“Our collaboration over the past years has greatly benefited our customers and both companies. The adapted agreement now reflects the dynamics of this rapidly evolving market, providing additional strategic flexibility for both partners,” commented Reinhard Vogt, Member of SSB’s Executive Committee.

SSB and Lonza have also entered into a further long-term agreement for supply of equipment and consumables. Under the new agreement, SSB will be a preferred supplier for specific Lonza projects. As Lonza increases its capacity for small-scale manufacturing, notably through the recently announced IbexTM Design and Develop in Visp (Switzerland), strong partnerships are key to offering the best solutions for customers. “We see us well positioned and are very much looking forward to supporting Lonza to implement next-generation manufacturing concepts at their Visp and other sites,” added Vogt.

Read More

Related news

Global collaboration to innovate more natural and additive-free nutraceuticals

Global collaboration to innovate more natural and additive-free nutraceuticals

11 Apr 2019

Initiative will enable Sirio Pharma to keep abreast of regional trends, new ingredients, dosage forms and claims to provide customers unique product ideas for line extensions.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
New China-based biotechs fueling growth in manufacturing across China

New China-based biotechs fueling growth in manufacturing across China

9 Apr 2019

New guidelines will see poorer quality manufacturers drop out of the market.

Read more 
TTP spin-out to commercialise next-generation cell-sorting technology

TTP spin-out to commercialise next-generation cell-sorting technology

7 Apr 2019

Highway 1 addresses a major unmet need for improved cell-sorting technology, with applications including development of cell therapies, liquid biopsy diagnostics, and high-throughput drug discovery.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more 
'Drugs from bugs' joint venture

'Drugs from bugs' joint venture

4 Apr 2019

Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.

Read more 
BASF launches three new active ingredients derived from the rambutan tree

BASF launches three new active ingredients derived from the rambutan tree

2 Apr 2019

The ingredients are extracted from the first organically certified rambutan gardens in Vietnam.

Read more 
Sartorius integrates online biomass measurement to its ambr systems for microbial applications

Sartorius integrates online biomass measurement to its ambr systems for microbial applications

1 Apr 2019

Scientists to rapidly obtain detailed process understanding and control over their microbial cultures.

Read more 
Cambrex doubles cGMP liquid filling capacity at its Mirabel facility

Cambrex doubles cGMP liquid filling capacity at its Mirabel facility

1 Apr 2019

Investment will improve production cycle time and provide greater flexibility to customers.

Read more